COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Acute Impact of the Impella CP Assist Device in Pts. With Cardiogenic Shock on the Patients Hemodynamic (JenaMACS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04451798
Recruitment Status : Recruiting
First Posted : June 30, 2020
Last Update Posted : June 30, 2020
Information provided by (Responsible Party):
Sven Möbius-Winkler, University of Jena

Brief Summary:
Prospective, monocentric open-label observational study for the assessment of acute hemodynamic effects following implantation of the IMPELLA CP cardiac support device

Condition or disease Intervention/treatment Phase
Cardiogenic Shock Device: Impella CP microaxial pump Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: JENA Mechanical Assist Circulatory Support Trial-JENAMACS-hemodynamic
Actual Study Start Date : December 2016
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : March 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock

Arm Intervention/treatment
Experimental: Intervention
Impella implantation and hemodynamic measurement
Device: Impella CP microaxial pump
ramp test

Primary Outcome Measures :
  1. Hemodynamic Parameters due to PA catheterisation [ Time Frame: Day 1 ]
    PCPW Pressure in dependence of Impella pump level

  2. Echocardiographic Parameters of left and right heart function [ Time Frame: Day 1 ]
    LV- size in dependence of Impella pump level

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 91 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cardiogenic shock following acute MI or acute heart failure with

    • systolic BP < 90 mm Hg over > 30 min or inotropes for support of cardiac output and BP with
    • signs of left heart failure and pulmonary congestion
    • and end-organ hypo perfusion with somnolence or cold, pale skin, or oliguria or serum lactate >2 mmol/l

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04451798

Layout table for location contacts
Contact: SWven Möbius-Winkler, MD 0049-3641-9324503
Contact: Christian P Schulze, MD 0049-3641-9324103

Layout table for location information
University of Jena Recruiting
Jena, Germany, 07747
Contact: Sven Möbius-Winkler, MD, PhD    0049-34619324503   
Sponsors and Collaborators
University of Leipzig
Layout table for investigator information
Principal Investigator: Sven Möbius-Winkler, MD Universityhospital Jena
Layout table for additonal information
Responsible Party: Sven Möbius-Winkler, Consultant, University of Jena Identifier: NCT04451798    
Other Study ID Numbers: SMW 07
First Posted: June 30, 2020    Key Record Dates
Last Update Posted: June 30, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Sven Möbius-Winkler, University of Jena:
Additional relevant MeSH terms:
Layout table for MeSH terms
Shock, Cardiogenic
Pathologic Processes
Myocardial Infarction
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases